![](../../files/images/goods/1069-66-5.png)
Valproic acid sodium salt
CAS No. 1069-66-5
Valproic acid sodium salt( Sodium Valproate )
Catalog No. M10288 CAS No. 1069-66-5
A HDAC inhibitor that selectively inhibits the catalytic activity of class I HDACs, and induces proteasomal degradation of HDAC2.
Purity : >98% (HPLC)
![](/themes/theme/en/images/pdf.png)
![](/themes/theme/en/images/pdf.png)
![](/themes/theme/en/images/pdf.png)
![](/themes/theme/en/images/pdf.png)
![](/themes/theme/en/images/pdf.png)
![](/themes/theme/en/images/pdf.png)
Size | Price / USD | Stock | Quantity |
500MG | 38 | In Stock |
![]() ![]() |
1G | 45 | In Stock |
![]() ![]() |
Biological Information
-
Product NameValproic acid sodium salt
-
NoteResearch use only, not for human use.
-
Brief DescriptionA HDAC inhibitor that selectively inhibits the catalytic activity of class I HDACs, and induces proteasomal degradation of HDAC2.
-
DescriptionA HDAC inhibitor that selectively inhibits the catalytic activity of class I HDACs, and induces proteasomal degradation of HDAC2; induces differentiation of carcinoma cells, transformed hematopoietic progenitor cells and leukemic blasts from AML patients; reduces tumor growth and metastasis formation in animal model.Migraine Approved(In Vitro):Valproic acid (VPA) (0-15 mM; 24 and 72 h) inhibits Hela cell growth in a dose- and time- dependent manner.Valproic acid (10 mM; 24 h) significantly attenuates the activities of total, cytosol and nuclear HDACs.Valproic acid (0-15 mM; 24 h) induces a G1 phase arrest at 1–3 mM and a G2/M phase arrest at 10 mM, and increases the percentage of sub-G1 cells in HeLa cells. Valproic acid also induces necrosis, apoptosis and lactate dehydrogenase (LDH) release.Valproic acid (0-20 mM; 24 h) activates Tcf/Lef-dependent transcription and synergizes with lithium.Valproic acid (0-5 mM; 0-18 h) increases β-catenin levels in Neuro2A cells.Valproic acid (0-2 mM; 0-24 h) stimulates phosphorylation of AMPK and ACC in hepatocytes.Valproic acid (0-10 mM; 2 days) induces Notch1 signaling and morphologic differentiation, suppresses production of NE tumor markers in SCLC cells.(In Vivo):Valproic acid (VPA) (500 mg/kg; i.p.; daily for 12 days) inhibits tumor angiogenesis in mice transplanted with Kasumi-1 cells.Valproic acid (350 mg/kg; i.p.; once) enhances social behavior in rats.Valproic acid (0.26% (w/v); p.o. via drinking water; 14 days) decreases liver mass, hepatic fat accumulation, and serum glucose in obese mice without hepatotoxicity.
-
In VitroValproic acid (VPA) (0-15 mM; 24 and 72 h) inhibits Hela cell growth in a dose- and time- dependent manner.Valproic acid (10 mM; 24 h) significantly attenuates the activities of total, cytosol and nuclear HDACs.Valproic acid (0-15 mM; 24 h) induces a G1 phase arrest at 1–3 mM and a G2/M phase arrest at 10 mM, and increases the percentage of sub-G1 cells in HeLa cells. Valproic acid also induces necrosis, apoptosis and lactate dehydrogenase (LDH) release.Valproic acid (0-20 mM; 24 h) activates Tcf/Lef-dependent transcription and synergizes with lithium.Valproic acid (0-5 mM; 0-18 h) increases β-catenin levels in Neuro2A cells.Valproic acid (0-2 mM; 0-24 h) stimulates phosphorylation of AMPK and ACC in hepatocytes.Valproic acid (0-10 mM; 2 days) induces Notch1 signaling and morphologic differentiation, suppresses production of NE tumor markers in SCLC cells. Cell Viability Assay Cell Line:HeLa cells Concentration:0, 1, 3, 5, 10 and 15 mM Incubation Time:24 and 72 h Result:HeLa cell growth was dose- and time-dependently decreased with an IC50 of ~10 and 4 mM at 24 and 72 h.Western Blot Analysis Cell Line:HeLa cells, Neuro2A cells or primary mouse hepatocytes Concentration:10 mM (HeLa); 0, 2, and 5 mM (Neuro2A); 0.2, 0.4, 0.8, 1.2 and 2 mM (hepatocytes)Incubation Time:24 h (HeLa); 0-18 h (Neuro2A); 0-24 h (hepatocytes) Result:Increased the form of acetylated histone 3. Reduced PARP, induced cleavage PARP, and downregulated Bcl-2. Increased β-catenin levels. Increased the phosphorylation of AMPK and ACC.Cell Cycle Analysis Cell Line:HeLa cells Concentration:0, 1, 3, 5, 10 and 15 mM Incubation Time:24 h Result:Induced a G1 phase arrest at 1–3 mM, significantly induced a G2/M phase arrest at 10 mM, and increased the percentage of sub-G1 cells in HeLa cells in a dose-dependent manner at 24 h.
-
In VivoValproic acid (VPA) (500 mg/kg; i.p.; daily for 12 days) inhibits tumor angiogenesis in mice transplanted with Kasumi-1 cells.Valproic acid (350 mg/kg; i.p.; once) enhances social behavior in rats.Valproic acid (0.26% (w/v); p.o. via drinking water; 14 days) decreases liver mass, hepatic fat accumulation, and serum glucose in obese mice without hepatotoxicity. Animal Model:Female BALB/c nude mice, Kasumi-1 tumor model Dosage:500 mg/kg Administration:Intraperitoneal injection, daily for 12 days Result:Inhibited tumor growth and tumor angiogenesis.Inhibited the mRNA and protein expression of VEGF, VEGFR2 and bFGF.Inhibited HDAC activity and increased acetylation of histone H3.Enhanced the accumulation of hyperacetylated histone H3 on VEGF promoters.
-
SynonymsSodium Valproate
-
PathwayCell Cycle/DNA Damage
-
TargetHDAC
-
RecptorGABAR|HDAC2|HDAC9
-
Research AreaNeurological Disease
-
IndicationMigraine
Chemical Information
-
CAS Number1069-66-5
-
Formula Weight166.1933
-
Molecular FormulaC8H15NaO2
-
Purity>98% (HPLC)
-
SolubilityH2O: ≥ 48 mg/mL
-
SMILESCCCC(CCC)C([O-])=O.[Na+]
-
Chemical NamePentanoic acid, 2-propyl-, sodium salt (1:1)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kr?mer OH, et al. EMBO J. 2003 Jul 1;22(13):3411-20.
2. G?ttlicher M, et al. EMBO J. 2001 Dec 17;20(24):6969-78.
3. Phiel CJ, et al. J Biol Chem. 2001 Sep 28;276(39):36734-41.
molnova catalog
![](/themes/theme/en/images/ct.png)
![](/themes/theme/en/images/new12.jpg)
![](/themes/theme/en/images/ct2.png)
related products
-
Apicidin
Apicidin (OSI 2040) is a fungal metabolite that exhibits potent, broad spectrum antiprotozoal activity in vitro.
-
Phenylethyl isothioc...
Phenylethyl isothiocyanate is an HDAC inhibitor. It potentially for the treatment of benign prostatic hypertrophy.
-
C5-benzyl SAHA
C5-benzyl SAHA is a C5-modified SAHA analog that displays dual selectivity to HDAC.